Communiqués Biodexa Pharmaceuticals Plc

Actions

BDRX

US59564R7089

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,871 ^USD	+3,43%		-12,02%	-67,50%

27/06	Les actions européennes négociées aux États-Unis sous forme de certificats de dépôt américains sont en hausse jeudi matin	MT
24/06	Les actions européennes négociées aux États-Unis et les American Depositary Receipts commencent la semaine en hausse dans les échanges de lundi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)	24/06	AQ
Results of Annual General Meeting	13/06	AQ
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona	10/06	AQ
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises	22/05	AQ
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting	21/05	AQ
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting	30/04	AQ
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)	26/04	AQ
Preliminary Results for the Year Ended 31 December 2023	19/04	AQ
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update	23/02	AQ
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients	08/02	AQ
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone	07/02	AQ
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024	22/01	AQ
Biodexa Appoints Ann Merchant to the Board of Directors	29/12	AQ
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option	21/12	AQ
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering	19/12	AQ
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes	27/11	AQ
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma	03/10/23	AQ
Biodexa Pharmaceuticals : SUBMITTED HEREWITH - Form 6-K	30/09/23	PU
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)	21/09/23	AQ
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites	28/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Biodexa Pharmaceuticals Plc

Actions

BDRX

US59564R7089

Communiqués

Filtres